Bismuth salts and neurotoxicity. A randomised,single-blind and controlled study

Abstract

The aim of this work was to investigate whether the nor mal use of colloidal bismuth subcitrate (CBS) and bismuth subnitrate (BSN) exhibits neurotoxic side-effects. A ran domised, single-blind controlled study was carried out in 66 patients with H. pylori associated gastritis. Patients were randomised to receive either amoxicillin (control group) for 4 weeks or BSN for 8 weeks or CBS for 8 weeks. Clinical and neurophysiological tests including elec troneurography (ENG) and spectral electroencephalogra phy (EEG) were performed before and after therapy. No clinically relevant changes were observed with clinical tests as well as with ENG and spectral EEG recordings within each group and between the groups. It was con cluded that the normal use of CBS and BSN does not exhibit clinical neurotoxicity.

Keywords

bismuth toxicity neurotoxicity colloidal bis muth subcitrate bismuth subnitrate electroneurography electroencephalography

Get full access to this article

View all access options for this article.

References

Marshall BJ The use of bismuth in gastroenterology. American Journal of Gastroenterology 1991; 86: 16-25.

Winship KA Toxicity of bismuth salts. Adverse Drug Reactions and Acute Poisoning Reviews 1983; 2: 103-121.

Slikkerveer A. & de Wolff FA Pharmacokinetics and toxicity of bismuth compounds . Medical Toxicology and Adverse Drug Experience 1989; 4: 303- 23.

Gorbach SL Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990; 99: 863-75.

Burns R. , Thomas DW & Barron VJ Reversible encephalopathy possibly associated with bismuth subgallate ingestion . British Medical Journal 1974; 1: 220-3.

Morrow AW Request for reports: Adverse reactions with bismuth subgallate. Medical Journal of Australia 1973; 1: 912.

Robertson JF Mental illness or metal illness? Bismuth subgallate . Medical Journal of Australia 1974; 1: 887-88.

Lowe DJ Adverse effects of bismuth subgallate-a further report from the Australian Drug Evaluation Committee. Medical Journal of Australia 1974; 2: 664-6.

Buge A. , Rancurel G. , Poisson M. & Dechy H. Encéphalopathie myoclonique par les sels de bismuth; six cas observés lors de traitement oraux au long cours. Nouvelle Presse Médicale 1974; 3: 2315-20.

10.

Lechat P. & Kisch R. Les encéphalopathies bismuthiques: réévaluation du risque. Gastroenterologie Clinique & Biologique 1986; 10: 562-9.

11.

Weller Mpi. Neuropsychiatric symptoms following bismuth intoxication. Postgraduate Medical Journal 1988; 64: 308-10.

12.

Bader JP The safety profile of De-Nol. Digestion 1987 ; 37 (suppl.2): 53-9.

13.

Playford RJ , Matthews CH , Campbell MJ , Delves HT , Hla KK , Hodgson Hjf , et al. Bismuth induced encephalopathy caused by tri potassium dicitrato bismuthate in a patient with chronic renal failure . Gut 1990; 31: 359-60.

14.

Von Bose MJ & Zaudig M. Encephalopathy resembling Creutzfeldt-Jakob disease following oral, prescribed doses of bismuth nitrate. British Journal of Psychiatry 1991; 158: 278-80.

15.

Hudson M. & Mowat AG Reversible toxicity in poisoning with colloidal bismuth subcitrate . British Medical Journal 1989; 299: 436.

16.

Supino-Viterbo V. , Sicard C. , Risvegliato M. , Rancurel G. & Buge A.

Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patients. Journal of Neurology, Neurosurgery &

Psychiatry 1977; 40: 748-52.

17.

Goas JY , Borsotti JP , Missoum A. , Allain P. & Chaleil D. Encephalopathie myoclonique par le sous-nitrate de bismuth. Une observation récente. Nouvelle Presse Médicale 1981; 10: 3855.

18.

Lagueny A. , Vallat J-M. & Julien J. Enregistrement électromyographique au cours des encéphalopathies par les sels de bismuth. Nouvelle Presse Medicale 1976; 5: 2252-3.

19.

Tytgat Gnj. Colloidal bismuth subcitrate in peptic ulcer - a review. Digestion 1987; 37 (suppl 2): 31-41.

20.

Wagstaff A. , Benfield P. & Monk JP Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 132- 57.

21.

Marshall BJ , McGechie DA , Rogers PA & Glancy RJ Pyloric Campylobacter infection and gastroduodenal disease. Medical Journal of Australia 1985 ; 142: 439-44.

22.

Armstrong JA , Wee SH , Goodwin CS & Wilson DH Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro — an ultrastructural study . Journal of Medical Microbiology 1987; 24: 343-50.

23.

Bayerdörffer E. & Ottenjann R. The role of antibiotics in Campylobacter pylori associated peptic ulcer disease. Scandinavian Journal of Gastroenterology 1988; 23 (suppl 142): 93-100.

24.

Tytgat Gnj , Noach LA & Rauws Eaj. Helicobacter pylori. European Journal of Gastroenterology & Hepatology 1992; 4 (suppl 1): S7-S15.

25.

Ongerboer de Visser BW , van der Sande JJ & Kemp B. Ulnar F-wave conduction velocity in epidural metastatic root lesions. Annals of Neurology 1982; 11: 142-6.

26.

Schimsheimer RJ , Ongerboer de Visser BW , Kemp B. & Bour LJ The flexor carpi radialis H-reflex in polyneuropathy: relation to conduction velocity of the median nerve and the soleus H-reflex latency. Journal of Neurology, Neurosurgery & Psychiatry 1987; 50: 447-52.

27.

Kwa Vih , Weinstein HC , Posthumus Meyjes EF, van Royen EA, Bour LJ, Verhoeff PNLG & Ongerboer de Visser BW. Spectral Analysis of the EEG and 99m-Io-HMPAD SPECT-scan in Alzheimer's Disease. Biological Psychiatry 1993; 33: 100-7.

28.

Slikkerveer A. , Helmich RB , Edelbroek PM , van der Voet GB & de Wolff FA Analysis of bismuth in serum and blood by electrothermal atomic absorption spectrometry using platinum as matrix modifier . Clinica Chimica Acta 1991; 201: 17-26.

29.

Slikkerveer A. , Terpstra IJ & de Wolff FA Citrate enhances intestinal absorption of bismuth in man. In: Slikkerveer A. Bismuth: Biokinetics, toxicity and experimental therapy of overdosage. Academic thesis, 1992; 103-115.

30.

Nuwer MR

Quantitative EEG: II. Frequency analysis and topographic mapping in clinical settings. Journal of Clinical

Neurophysiology 1988; 5: 45-85.

31.

Nuwer MR

Quantitative EEG: I. Techniques and problems of frequency analysis and topographic mapping. Journal of Clinical

Neurophysiology 1988; 5 1-43.

32.

Nwokolo CU , Prewett EJ , Sawyerr AM & Pounder RE Lack of bismuth absorption from bismuth subnitrate (Roter) tablets . European Journal of Gastroenterology & Hepatology 1990 ; 2: 433-5.

33.

Nwokolo CU , Mistry P. & Pounder RE The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate). Alimentary Pharmacology & Therapeutics 1990; 4: 163-70.

34.

Madaus S. , Schulte-Frohlinde E. , Scherer C, Kämmereit, Schusdziarra V & Classen M. Comparison of plasma bismuth levels after oral dosing with basic bismuth carbonate or tripotassium dicitrato bismuthate. Alimentary Pharmacology & Therapeutics 1992; 6: 241-9.

35.

Nwokolo CU , Gavey CJ , Smith Jtl & Pounder RE The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate . Alimentary Pharmacology & Therapeutics 1989; 3: 29-39.

36.

Conso F. , Bourdon R. & Gaultier M. Bismuth sanguin et urinaire après traitement bref par différents sels 'insolubles' de bismuth. European Journal of Toxicology 1975; 8: 137-41.

37.

Mendelowitz PC , Hoffman RS & Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Annals of Internal Medicine 1990; 112: 140-1.

38.

Gavey CJ , Szeto ML , Nwokolo CU , Sercombe J. & Pounder RE Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate. Alimentary Pharmacology & Therapeutics 1989; 3: 21-8.

39.

Escourolle R. , Bourdon R. , Galli A. , Galle P. , Jaudon MC , Hauw JJ , et al. Étude neuropathologique et toxicologique de douze cas d'encéphalopathie bismuthique. Reviews in Neurology 1977; 133: 153-63.